ArticleLeukemia2022
In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance.
Anna-Katharina Wirth et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
16 papers cite it
this papercites it